UGT1A1 and cancer: This systematic review confirms the usefulness of UGT1A1*28 and/or *6 genotyping prior to the treatment start with irinotecan, regardless of the chemotherapy regimen and the type of cancer, leading to different MTDs depending on the genotype and confirming these results with PK studies in some of the included trials (Table 4).